Inhibitory influence of the hexapeptidic sequence SLIGRL on influenza A virus infection in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 3, 2012, Pages 725-735

  Betts, Richard J ^a   Mann, Tracy S ^a   Henry, Peter J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 FUROYL LEUCYLGLYCYLISOLEUCYLARGINYLLEUCINAMIDE; ANTIVIRUS AGENT; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; ISOLEUCYLGLYCYLARGINYLLEUCINAMIDE; KERATINOCYTE DERIVED CHEMOKINE; LEUCYLSERYLISOLEUCYLGLYCYLARGINYLLEUCINAMIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MAS RELATED G PROTEIN COUPLED RECEPTOR C11; METHACHOLINE; POLYPEPTIDE; PROTEINASE ACTIVATED RECEPTOR; SERYLLEUCYLISOLEUCYLARGINYLGLYCYLLEUCINAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; EX VIVO STUDY; HISTOPATHOLOGY; IC 50; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VIRUS A; LEUKOCYTE COUNT; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MALE; MOUSE; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; SINGLE DRUG DOSE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CYTOKINES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLUENZA A VIRUS; LEUKOCYTE COUNT; LEUKOCYTES; LUNG; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, SCANNING; OLIGOPEPTIDES; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTOR, PAR-2; RESPIRATORY FUNCTION TESTS; TRACHEA; VIRUS REPLICATION;

EID: 84869217527     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.196485     Document Type: Article

References (39)

1. 2-derived peptide ligands. J Pharmacol Exp Ther 290:753-760.
2. Al-Ani B, Saifeddine M, Wijesuriya SJ, and Hollenberg MD (2002) Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin. J Pharmacol Exp Ther 300:702-708.
3. Dale C and Vergnolle N (2008) Protease signaling to G protein-coupled receptors: implications for inflammation and pain. J Recept Signal Transduct Res 28:29-37. (Pubitemid 351588074)
4. Fazekas de St Groth S and White DO (1958) An improved assay for the infectivity of in influenza viruses. J Hyg (Lond) 56:151-162.
5. Feld M, Shpacovitch VM, Ehrhardt C, Kerkhoff C, Hollenberg MD, Vergnolle N, Ludwig S, and Steinhoff M (2008) Agonists of proteinase-activated receptor-2 enhance IFN-γ-inducible effects on human monocytes: role in influenza A infection. J Immunol 180:6903-6910.
6. Georgy SR, Pagel CN, Wong DM, Sivagurunathan S, Loh LH, Myers DE, Hollenberg MD, Pike RN, and Mackie EJ (2010) Proteinase-activated receptor-2 (PAR2) and mouse osteoblasts: regulation of cell function and lack of specificity of PAR2-activating peptides. Clin Exp Pharmacol Physiol 37:328-336.
7. Guo CT, Takahashi T, Bukawa W, Takahashi N, Yagi H, Kato K, Hidari KI, Miyamoto D, Suzuki T, and Suzuki Y (2006) Edible bird's nest extract inhibits influenza virus infection. Antiviral Res 70:140-146. (Pubitemid 44226306)
8. Hollenberg MD and Compton SJ (2002) International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54:203-217. (Pubitemid 34575710)
9. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, et al. (2009) Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 83:90-93.
10. Jones JC, Turpin EA, Bultmann H, Brandt CR, and Schultz-Cherry S (2006) Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 80:11960-11967. (Pubitemid 44904345)
11. Kawabata A, Kanke T, Yonezawa D, Ishiki T, Saka M, Kabeya M, Sekiguchi F, Kubo S, Kuroda R, Iwaki M, et al. (2004) Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo. J Pharmacol Exp Ther 309:1098-1107. (Pubitemid 38669697)
12. Kawabata A, Nishikawa H, Kuroda R, Kawai K, and Hollenberg MD (2000) Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. Br J Pharmacol 129:1808-1814. (Pubitemid 30219027)
13. Kesimer M, Scull M, Brighton B, DeMaria G, Burns K, O'Neal W, Pickles RJ, and Sheehan JK (2009) Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J 23:1858-1868.
14. Khoufache K, LeBouder F, Morello E, Laurent F, Riffault S, Andrade-Gordon P, Boullier S, Rousset P, Vergnolle N, and Riteau B (2009) Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-γ-dependent pathway. J Immunol 182:7795-7802.
15. Lan RS, Knight DA, Stewart GA, and Henry PJ (2001) Role of PGE2 in protease-activated receptor-1, -2 and -4 mediated relaxation in the mouse isolated trachea. Br J Pharmacol 132:93-100. (Pubitemid 32128438)
16. Lan RS, Stewart GA, Goldie RG, and Henry PJ (2004) Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice. Am J Physiol Lung Cell Mol Physiol 286:L388-L398. (Pubitemid 38129521)
17. Lan RS, Stewart GA, and Henry PJ (2000) Modulation of airway smooth muscle tone by protease activated receptor-1, -2, -3 and -4 in trachea isolated from influenza A virus-infected mice. Br J Pharmacol 129:63-70. (Pubitemid 30072672)
18. Lee MG, Dong X, Liu Q, Patel KN, Choi OH, Vonakis B, and Undem BJ (2008) Agonists of the MAS-related gene (Mrgs) orphan receptors as novel mediators of mast cell-sensory nerve interactions. J Immunol 180:2251-2255.
19. Liu Q, Weng HJ, Patel KN, Tang Z, Bai H, Steinhoff M, and Dong X (2011) The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal 4:ra45.
20. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, and Plevin R (2001) Proteinaseactivated receptors. Pharmacol Rev 53:245-282.
21. Magden J, Kääriäinen L, and Ahola T (2005) Inhibitors of virus replication: recent developments and prospects. Appl Microbiol Biotechnol 66:612-621. (Pubitemid 40385623)
22. Mall MA (2008) Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 21:13-24.
23. McGuire JJ, Dai J, Andrade-Gordon P, Triggle CR, and Hollenberg MD (2002) Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J Pharmacol Exp Ther 303:985-992. (Pubitemid 35424380)
24. McNicholl IR and McNicholl JJ (2001) Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother 35:57-70. (Pubitemid 32216283)
25. Müller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, and Kainov DE (2012) Emerging cellular targets for influenza antiviral agents. Trends Pharmacol Sci 33:89-99.
26. Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, Fasano A, and Vogel SN (2010) Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol 3:29-39.
27. Nishikawa H, Kawai K, Tanaka M, Ohtani H, Tanaka S, Kitagawa C, Nishida M, Abe T, Araki H, and Kawabata A (2005) Protease-activated receptor-2 (PAR-2)-related peptides induce tear secretion in rats: involvement of PAR-2 and non-PAR-2 mechanisms. J Pharmacol Exp Ther 312:324-331. (Pubitemid 40096485)
28. Numata M, Kandasamy P, Nagashima Y, Posey J, Hartshorn K, Woodland D, and Voelker DR (2012) Phosphatidylglycerol suppresses influenza A virus infection. Am J Respir Cell Mol Biol 46:479-487.
29. Nystedt S, Emilsson K, Wahlestedt C, and Sundelin J (1994) Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 91:9208-9212. (Pubitemid 24297883)
30. Pittet LA, Hall-Stoodley L, Rutkowski MR, and Harmsen AG (2010) Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol 42:450-460.
31. Rajik M, Jahanshiri F, Omar AR, Ideris A, Hassan SS, and Yusoff K (2009) Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2. Virol J 6:74.
32. Salomon R and Webster RG (2009) The influenza virus enigma. Cell 136:402-410.
33. Shpacovitch V, Feld M, Bunnett NW, and Steinhoff M (2007) Protease-activated receptors: novel PARtners in innate immunity. Trends Immunol 28:541-550.
34. Sidwell RW and Smee DF (2000) In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 48:1-16.
35. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, and Hollenberg MD (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1-43. (Pubitemid 40209385)
36. Takeda M, Pekosz A, Shuck K, Pinto LH, and Lamb RA (2002) Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 76:1391-1399. (Pubitemid 34070633)
37. Vergnolle N, Hollenberg MD, Sharkey KA, and Wallace JL (1999) Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 127:1083-1090. (Pubitemid 29326629)
38. White MR, Doss M, Boland P, Tecle T, and Hartshorn KL (2008) Innate immunity to influenza virus: implications for future therapy. Expert Rev Clin Immunol 4:497-514. (Pubitemid 351903267)
39. Williams K and MacKenzie JS (1977) Influenza infections during pregnancy in the mouse. J Hyg (Lond) 79:249-257. (Pubitemid 8213291)